Interview with Dr Bright on psychedelic psychotherapy

abc.bris_.sb_.6dec16

Dr Stephen Bright, a Psychologist working at Curtin University discusses psychedelic therapy. He explains that psychedelic therapy involves a traditional psychotherapeutic context. He says that these medical drugs have been used to treat anxiety, depression and alcohol dependency. According to Bright, research from Johns Hopkins School of Medicine and UCLA shows that psychedelic therapy has had positive results in helping people with cancer to cope with their disease. Dr Bright mentions that the information that the Nixon Government spread about LSD, psilocybin and mescaline is wrong. In fact these medicines are non-addictive, have low acute toxicity and there have been no reports of deaths from LSD overdose. Bright also explains that MDMA allows people with PTSD to be more open to re-experiencing their traumatic event, and it assists them to reprocess it. He says that Australia will continue to fall behind in therapeutic treatments if Australian researchers and politicians don’t embrace psychedelic science.

Listen to the interview here: https://youtu.be/OqHc8rDhDxs

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email

Innovative psychedelic research

The re-emergence of psychedelic research places a crucial emphasis on a holistic approach to mental health from pharmacology, neurobiological process, ecological connection, and therapeutic support.  PRISM supports research and clinical development of therapies where current options provide limited relief.

Your support allows us to pursue cutting edge research for next-generation mental health care.

PRISM

We are a DGR-1 non-profit research charity developing medical and legal processes for the application of psychedelic medicines for improved wellbeing.

Newsletter

Contact Us

Send us an email and we'll get back to you soon.

Not readable? Change text. captcha txt

Start typing and press Enter to search